Compare
Janux Therapeutics, Inc. vs Zenas BioPharma, Inc. vs Precigen, Inc. vs Crescent Biopharma, Inc.
| Latest fiscal year | Janux Therapeutics, Inc. JANX | Zenas BioPharma, Inc. ZBIO | Precigen, Inc. PGEN | Crescent Biopharma, Inc. CBIO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $10.00M | $10.00M | $9.68M | $10.84M |
| Revenue growth (YoY) | -5.6% | +100.0% | +146.7% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$113.62M | -$377.74M | -$250.64M | -$153.94M |
| EPS (Diluted) | -$1.83 | -$8.44 | -$1.37 | n/a |
| Operating cash flow | -$82.23M | -$172.33M | -$87.83M | -$71.53M |
| Free cash flow | -$83.28M | -$172.35M | -$89.83M | -$72.45M |
| Cash & equivalents | $52.33M | $110.64M | $30.23M | $213.19M |
| Total assets | $1.00B | $383.64M | $155.50M | $240.29M |
| Total liabilities | $44.74M | $141.50M | $134.59M | $37.28M |
| Shareholders' equity | $956.82M | $242.14M | $20.91M | $203.01M |
| Return on year-end equity | -11.9% | -156.0% | n/m | -75.8% |
| Shares outstanding | 60.38M | 54.49M | 353.91M | 27.56M |
Revenue, most recent five fiscal years
| Fiscal year | Janux Therapeutics, Inc. | Zenas BioPharma, Inc. | Precigen, Inc. | Crescent Biopharma, Inc. |
|---|---|---|---|---|
| Latest | $10.00M Ended 2025-12-31 | $10.00M Ended 2025-12-31 | $9.68M Ended 2025-12-31 | $10.84M Ended 2025-12-31 |
| 1 year earlier | $10.59M Ended 2024-12-31 | $5.00M Ended 2024-12-31 | $3.92M Ended 2024-12-31 | n/a |
| 2 years earlier | $8.08M Ended 2023-12-31 | $50.00M Ended 2023-12-31 | $6.22M Ended 2023-12-31 | n/a |
| 3 years earlier | $8.61M Ended 2022-12-31 | n/a | $26.91M Ended 2022-12-31 | n/a |
| 4 years earlier | $3.64M Ended 2021-12-31 | n/a | $14.27M Ended 2021-12-31 | n/a |